Neuphoria Therapeutics Inc 6-K, filed Nov 16, 2022
Neuphoria Therapeutics Inc. (NEUP)
About this 6-K
Neuphoria Therapeutics Inc filed this 6-K on November 16, 2022.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
OF THE SECURITIES EXCHANGE ACT OF 1934
For the month of November, 2022
(Commission File No. 001-41157)
BIONOMICS LIMITED
(Translation of registrant’s name into English)
200 Greenhill Road
Eastwood SA 5063
Tel: +618 8150 7400
(Address of registrant’s principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101 (b) (1):
Yes ☐ No ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101 (b) (7):
Yes ☐ No ☐
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes ☐ No ☐
INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K
In regard to its Annual General Meeting held in Australia on November 16, 2022, the Company has lodged the Results of the Meeting with the Australian Securities Exchange (ASX), as required by the laws and regulations of Australia. That document is furnished herewith as Exhibit 99.1 to this report on Form 6-K.
1
EXHIBIT INDEX
|
|
Exhibit
|
Description
|
99.1 |
|
|
|
|
|
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereto duly authorized.
|
|
|
|
Bionomics Limited |
|
|
(Registrant) |
|
|
|
|
|
By: |
/s/ Errol De Souza
|
|
Name: |
Errol De Souza, Ph.D. |
|
Title: |
Executive Chairman |
Date: November 16, 2022
1
Exhibit 99.1
ABN 53 075 582 740
16 November 2022
ASX Market Announcements ASX Limited
Level 4
Stock Exchange Centre 20 Bridge Street
SYDNEY NSW 2000
Dear Sir/Madam,
RESULTS OF ANNUAL GENERAL MEETING
In accordance with Listing Rule 3.13.2 and section 251AA of the Corporations Act, the attached document provides details of the proxies received and the manner in which votes were cast for each resolution.
This announcement was authorised for release by the Company Secretary.
FOR FURTHER INFORMATION PLEASE CONTACT:
Ms Suzanne Irwin Company Secretary
+61 8 8150 7400
CoSec@bionomics.com.au
About Bionomics Limited
Bionomics (ASX:BNO, OTCQB:BNOEF) is a clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (“CNS”) disorders with high unmet medical need. Bionomics is advancing its lead product candidate, BNC210, an oral proprietary selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor, for the acute treatment of Social Anxiety Disorder (“SAD”) and chronic treatment of Post-Traumatic Stress Disorder (“PTSD”). Beyond BNC210, Bionomics has a strategic partnership with Merck & Co., Inc (known as MSD outside the United States and Canada) with two drugs in early-stage clinical trials for the treatment of cognitive deficits in Alzheimer’s disease and other central nervous system conditions.
www.bionomics.com.au
BIONOMICS LIMITED
ANNUAL GENERAL MEETING
Wednesday, 16 November 2022
Results of Meeting
The following information is provided in accordance with section 251AA(2) of the Corporations Act 2001 (Cth) and ASX Listing Rule 3.13.2.
Resolution details |
Instructions given to validly appointed proxies (as at proxy close) |
Number of votes cast on the poll (where applicable) |
Resolution Result |
||||||
Resolution |
Resolution Type |
For |
Against |
Proxy's Discretion |
Abstain |
For |
Against |
Abstain* |
Carried / Not Carried |
1. Adoption of Remuneration Report |
Ordinary |
348,518,059 96.50% |
11,162,111 3.09% |
1,457,982 0.41% |
1,685,701 |
363,914,938 97.02% |
11,167,811 2.98% |
1,685,701 |
Carried |
2. Re-election of Mr Alan Fisher as a Director of the Company |
Ordinary |
352,110,170 97.44% |
7,829,138 2.16% |
1,460,110 0.40% |
1,988,762 |
367,584,861 97.86% |
8,029,138 2.14% |
1,988,762 |
Carried |
3. Approval of issue of Shares – Future Placement Facility |
Ordinary |
348,008,029 95.87% |
13,550,209 3.73% |
1,457,982 0.40% |
371,960 |
363,480,592 96.35% |
13,750,209 3.65% |
371,960 |
Carried |
4. Approval of 10% Placement Facility |
Special |
348,746,387 96.07% |
12,792,951 3.53% |
1,457,982 0.40% |
390,860 |
364,213,250 96.55% |
12,998,651 3.45% |
390,860 |
Carried |
‘*Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll. |
|||||||||